DekaBank Deutsche Girozentrale Lowers Stake in Cencora, Inc. (NYSE:COR)

DekaBank Deutsche Girozentrale decreased its position in Cencora, Inc. (NYSE:COR - Free Report) by 1.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 532,888 shares of the company's stock after selling 10,125 shares during the period. DekaBank Deutsche Girozentrale owned approximately 0.27% of Cencora worth $144,086,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hoey Investments Inc. acquired a new position in shares of Cencora during the 1st quarter worth about $28,000. Banque Transatlantique SA acquired a new position in shares of Cencora during the 4th quarter worth approximately $29,000. SBI Securities Co. Ltd. acquired a new position in shares of Cencora during the 4th quarter worth approximately $30,000. Vermillion Wealth Management Inc. acquired a new position in shares of Cencora during the 4th quarter worth approximately $38,000. Finally, Golden State Wealth Management LLC grew its position in shares of Cencora by 157.6% during the 1st quarter. Golden State Wealth Management LLC now owns 170 shares of the company's stock worth $47,000 after purchasing an additional 104 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

COR has been the topic of a number of recent analyst reports. Robert W. Baird lifted their price objective on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Citigroup boosted their price target on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Bank of America increased their target price on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Finally, Morgan Stanley set a $288.00 price target on shares of Cencora in a research note on Tuesday, April 15th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $306.33.

Cencora Trading Up 0.1%

Shares of NYSE:COR traded up $0.35 during mid-day trading on Wednesday, reaching $298.38. 186,311 shares of the company's stock were exchanged, compared to its average volume of 1,503,548. The business's fifty day moving average price is $291.57 and its 200-day moving average price is $268.53. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35. The firm has a market capitalization of $57.83 billion, a price-to-earnings ratio of 34.59, a PEG ratio of 1.50 and a beta of 0.57. The company has a debt-to-equity ratio of 6.01, a quick ratio of 0.52 and a current ratio of 0.87.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The business had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. During the same quarter in the previous year, the business earned $3.80 earnings per share. Cencora's revenue for the quarter was up 10.3% on a year-over-year basis. On average, research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.74%. The ex-dividend date was Friday, May 16th. Cencora's payout ratio is presently 25.52%.

Insider Transactions at Cencora

In related news, CEO Robert P. Mauch sold 4,969 shares of the company's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the sale, the chief executive officer directly owned 47,582 shares in the company, valued at approximately $13,766,900.06. This represents a 9.46% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the sale, the chairman owned 311,913 shares in the company, valued at $91,271,982.06. The trade was a 4.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 34,127 shares of company stock valued at $9,812,296 over the last ninety days. 10.80% of the stock is currently owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.